The Latest Breaking News from Scilex Holding Company

Sorrento's Scilex Unit Begins Mid-stage Study of Lower Back Pain Drug

Scilex Holding Company, a Sorrento Company (NASDAQ: SRNE) announced dosing of the first patient in a Phase 2 study of its drug candidate in patients with SP-103 in subjects with acute low back pain (LBP).

Benzinga · May 18, 2022

Sorrento's Pain Company Reveals Final Results For SP-102 Data For Sciatica Pain Management

Sorrento Therapeutics Inc's (NASDAQ: SRNE) subsidiary Scilex Holding Company has announced final results from its SP-102 Phase 3 Pivotal Trial C.L.E.A.R. Program.  SP-102 (Semdexa) has received Fast Track status from the FDA.

Benzinga · Mar 18, 2022

Vickers Venture SPAC To Merge With Sorrento Therapeutics' Pain-Focused Subsidiary

Vickers Venture Partners' special purpose acquisition company Vickers Vantage Corp I (NASDAQ: VCKA) will merge with Scilex Holding Company, focused on developing and commercializing non-opioid therapies for acute and chronic pain.

Benzinga · Mar 18, 2022